Bio-Path Holdings Secures Funding through Private Placement, Aims to Bolster Cancer Drug Development
Houston-based biotechnology company, Bio-Path Holdings, Inc. has recently announced a definitive agreement for the issuance and sale of shares of its common stock, alongside series A and short-term series B warrants, in a private placement priced at-the-market under Nasdaq rules. The company aims to raise an aggregate of $4.0 million through this funding, which will be utilized to further advance its portfolio of targeted nucleic acid cancer drugs. The offering is expected to close on or about June 5, 2024, subject to customary closing conditions.
Bio-Path Holdings is renowned for its proprietary DNAbilize liposomal delivery and antisense technology, which has shown significant potential in developing innovative cancer treatment solutions. By leveraging these unique resources, the company aims to address the unmet medical needs in oncology and provide novel therapies to patients.
Under the terms of the private placement, Bio-Path will issue and sell 1,809,955 shares of its common stock, or common stock equivalents, at a purchase price of $2.21 per share. Additionally, the company will offer series A warrants to purchase up to 1,809,955 shares of common stock, as well as short-term series B warrants to purchase up to the same number of shares. Both the series A and short-term series B warrants will have an exercise price of $2.00 per share and will be exercisable immediately upon issuance. The series A warrants will expire five years from the date of issuance, while the short-term series B warrants will expire in twenty-four months.
This private placement is expected to provide Bio-Path Holdings with the necessary financial resources to drive its research and development efforts forward. By securing this funding, the company can accelerate the development of its targeted nucleic acid cancer drugs, potentially bringing them closer to market and offering hope to patients in need.
This announcement comes shortly after Bio-Path Holdings reported an increase in current liabilities in the first quarter of 2024, leading to a decline in its Quick Ratio. The Quick Ratio, a measure of a company’s ability to meet short-term obligations with its most liquid assets, fell to a new company low of 0.05. This dip in the Quick Ratio was primarily attributed to the jump in current liabilities, totaling $3.812 million in the first quarter of 2024.
Analyzing the Quick Ratio on a trailing twelve-month basis, Bio-Path Holdings’ cumulative Quick Ratio decreased to 0.83 due to the rise in current liabilities in the first quarter of 2024. This figure falls below the company’s trailing twelve-month average Quick Ratio, highlighting the impact of the increase in liabilities on its financial position.
The private placement offering provides a timely solution to address the company’s financial challenges and bolster its ability to meet its short-term obligations. By raising $4.0 million through this funding, Bio-Path Holdings will be better equipped to manage its current liabilities while focusing on its core mission of developing targeted nucleic acid cancer drugs.
In conclusion, Bio-Path Holdings’ decision to enter into a definitive agreement for a private placement demonstrates the company’s commitment to advancing their portfolio of targeted nucleic acid cancer drugs. By securing $4.0 million in funding, Bio-Path Holdings can address its short-term financial obligations while investing in innovative research and development initiatives. This private placement marked a significant milestone for the company and is expected to accelerate its progress towards bringing promising cancer treatments to market.
Comments